Naviter Wealth LLC Sells 1,615 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Naviter Wealth LLC lowered its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 3.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 52,004 shares of the company’s stock after selling 1,615 shares during the quarter. Naviter Wealth LLC’s holdings in Takeda Pharmaceutical were worth $742,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. XY Capital Ltd grew its stake in shares of Takeda Pharmaceutical by 432.5% during the fourth quarter. XY Capital Ltd now owns 765,137 shares of the company’s stock valued at $10,919,000 after buying an additional 621,440 shares during the last quarter. FMR LLC grew its position in Takeda Pharmaceutical by 4.7% in the 3rd quarter. FMR LLC now owns 2,593,350 shares of the company’s stock valued at $40,119,000 after acquiring an additional 115,947 shares during the last quarter. Brandes Investment Partners LP increased its stake in Takeda Pharmaceutical by 2.1% in the third quarter. Brandes Investment Partners LP now owns 1,802,036 shares of the company’s stock worth $27,877,000 after purchasing an additional 36,717 shares during the period. Citigroup Inc. lifted its position in shares of Takeda Pharmaceutical by 5.6% during the third quarter. Citigroup Inc. now owns 57,941 shares of the company’s stock worth $896,000 after purchasing an additional 3,089 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical during the third quarter valued at $2,105,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 0.1 %

NYSE TAK opened at $13.18 on Tuesday. Takeda Pharmaceutical Company Limited has a 12 month low of $13.01 and a 12 month high of $17.11. The company’s 50-day moving average price is $14.03 and its 200-day moving average price is $14.17. The stock has a market cap of $41.71 billion, a PE ratio of 19.95, a PEG ratio of 2.97 and a beta of 0.53. The company has a current ratio of 1.06, a quick ratio of 0.55 and a debt-to-equity ratio of 0.64.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, February 1st. The company reported $0.51 EPS for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. The business had revenue of $7.52 billion for the quarter. Equities research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.5 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.